Paper Details

  1. Home
  2. Paper Details

[Advances in lung cancer].

Author: PautierP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The 28th Annual Meeting of ASCO focused on non-small cell lung cancer (NSCLC). Accurate staging, particularly for stage IIIA, is crucial, as tumor size and lymph node involvement influence treatment outcomes. Neoadjuvant therapy before surgery for stage IIIA and new drugs like Navelbine, taxol, and campthotecine hold promise for improving NSCLC chemotherapy. For small cell lung cancer (SCLC), trials are exploring ways to improve dose intensity using growth factors, therapy fractionation, and autologous bone marrow transplantation.
Paper Details　
Original Abstract of the Article :
Sessions about lung cancer of the 28th annual meeting of ASCO approached especially non small cell lung cancer (NSCLC). Undoubtedly the outstanding facts for this pathology was first the acknowledgment of the importance of a correct staging system, in particular in stage IIIA for which resection is ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1363892

データ提供：米国国立医学図書館（NLM）

Advances in Lung Cancer: A Glimpse into the Future

Lung cancer remains a significant health challenge, and research efforts are continuously underway to improve diagnosis, treatment, and outcomes. This report summarizes key developments presented at the 28th annual meeting of the American Society of Clinical Oncology (ASCO), focusing on advancements in non-small cell lung cancer (NSCLC).

The report highlights the importance of accurate staging for NSCLC, particularly for stage IIIA tumors. It discusses the role of neoadjuvant therapy before surgery for stage IIIA NSCLC and the potential of new drugs, such as Navelbine, Taxol, and camptothecine, to enhance chemotherapy regimens for NSCLC. The report also touches upon advancements in the treatment of small cell lung cancer (SCLC), including efforts to optimize dose intensity and explore the use of growth factors, fractionation of therapy, and autologous bone marrow transplantation.

A Quest for Better Treatments

This report underscores the ongoing quest for better treatments for lung cancer. The advancements discussed at the ASCO meeting offer promising avenues for improving patient outcomes and potentially extending lives.

Implications for Health and Lifestyle

If you or someone you know has been diagnosed with lung cancer, it is essential to seek specialized medical care. Early detection, accurate staging, and timely treatment are crucial for improving treatment success and quality of life.

Dr. Camel's Conclusion

The desert of lung cancer research continues to evolve, with new discoveries and innovative strategies emerging like desert blooms. These advances offer hope for a brighter future for patients battling this formidable disease.

Date :
  1. Date Completed 1993-06-21
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

1363892

DOI: Digital Object Identifier

1363892

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.